Endometrial tumors expressing higher SOX17 levels are associated with higher recurrence-free survival rates; conversely, progression of endometrial cancer may be promoted by low SOX17 expression through downregulation of MAML3 expression and Wnt signaling (57). Here, SOX17 is linked to endometrium neoplasm.